Ideaya Biosciences

IDYA51

$27.79arrow_drop_down5.68%-$1.67

IDYA51

$27.79

arrow_drop_down5.68%-$1.67

Performance History

Key Stats
Open	$30.52
Prev. Close	$30.49
EPS	-2.26
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	29.63	30.49
52 Week Range	23.41	47.73

Ratios







EPS	-2.26

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Ideaya Biosciences (IDYA)

Ideaya Biosciences Inc (IDYA) is a biotechnology company that focuses on the discovery and development of targeted therapeutics for patients with genomically defined cancers. The company's mission is to deliver transformative medicines to patients based on deep understanding of cancer biology and therapeutic targets. With a commitment to precision medicine, Ideaya Biosciences employs a proprietary synthetic lethality platform and a deep understanding of patient genetics to identify and develop potential therapies. The company's innovative approach has the potential to revolutionize cancer treatment and improve patient outcomes.

As of the latest stock price history, Ideaya Biosciences Inc (IDYA) has shown strong growth and resilience in the market. The stock has consistently performed well, with a steady increase in value over time. This positive trend is a testament to the company's innovative pipeline and promising drug candidates. Investors have taken notice of Ideaya Biosciences' potential, resulting in a significant rise in the company's market capitalization.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Yujiro S. Hata
Headquarters: South San Francisco
Employees: 116
Exchange: NASDAQ

Keep an eye on Ideaya Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Ideaya Biosciences (IDYA)?

Ideaya Biosciences (IDYA) has a market capitalization of $2.55B. The average daily trading volume is 28.49, indicating the stock's liquidity and investor engagement.

help

What is Ideaya Biosciences 's (IDYA) price per share?

The current price per share for Ideaya Biosciences (IDYA) is $27.8. The stock has seen a price change of -$1.67 recently, indicating a -5.68% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Ideaya Biosciences (IDYA)?

For Ideaya Biosciences (IDYA), the 52-week high is $47.74, which is 71.72% from the current price. The 52-week low is $23.41, the current price is 18.74% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Ideaya Biosciences (IDYA) a growth stock?

Ideaya Biosciences (IDYA) has shown an average price growth of -4.94% over the past three years. It has received a score of 70 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Ideaya Biosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Ideaya Biosciences (IDYA) stock price performance year to date (YTD)?

As of the latest data, Ideaya Biosciences (IDYA) has a year-to-date price change of -21.07%. Over the past month, the stock has experienced a price change of -8.77%. Over the last three months, the change has been -24.4%. Over the past six months, the figure is -33.5%. Looking at a longer horizon, the five-year price change stands at 243.19%.

help

Is Ideaya Biosciences (IDYA) a profitable company?

Ideaya Biosciences (IDYA) has a net income of -$112.96M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 82.86% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -5.73K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $23.38M, although specific revenue growth data is currently not available. The gross profit is $19.38M. Operating income is noted at -$134.43M. Furthermore, the EBITDA is -$222.31M.